To inquire about our available technologies, call our office (813) 745-6828

Name & Description Number
Protein Diagnostic: Characterization of Quantum Dots for Ovarian Cancer Detection 04A064
Protein Signature: Proteomics Signature: Discriminating Common Adenocarcinomas 05A014
Genetic Signature: Metastatic Melanoma Stage Identification 06B073
Plasma Protein Biomarker: Diagnosis of Ovarian Cancer 06B098
Protein Biomarker: Predicting Response to Immunosuppression in MDS 07A056
Genetic Signature: Predicting Tumor Aggressiveness 07B108
Protein Biomarker: Diagnostic Marker for AML and MPD 07B113
Genetic Signature: Malignancy Risk Signature to Predict High-Risk Normal Breast Tissues 08A016
Antibody Diagnostic: Monitoring Multiple Myeloma Progression and Recurrence 08MA005
Genetic Signature: Lymph Node Formation for Prognosis of Colorectal Cancer 09MA014
Protein Biomarker/Genetic Signature: Diagnostic for the Classification of Carcinomas of Unknown Primary Site (CUP) 10MA009
Genetic Signature: Methods of Predicting High Grade Glioma Outcomes Using Senescence Associated Genes 10MA013
Molecular Imaging Probe: Non-invasive Detection of Breast Cancer in Lymph Nodes 10MA024
Molecular Imaging Probe: Fluorescent and MRI Targeted Probes for the Melanocortin Receptor 1 on Melanomas, and Micelle Complexes for Drug Delivery 10MB069N
Genetic Signature: CREB Pathway Gene Signature to Determine which Ovarian Cancer Patients would have a Survival Benefit from Optimal Surgical Debulking 11MA006
Protein Diagnostic: Protein-Protein Interaction (PPI) Biomarkers 11MA014
Molecular Imaging Probe: Surrogate Markers for Colon Adenoma and Adenocarcinoma 11MA026N
Genetic Signature: Method of Detecting MDS Using hTERT Activity 11MB061N
Molecular Imaging Probe: Intraoperative Detection of Pancreatic Cancer Using Targeted Fluorescent Probes 11MB064
Genetic Signature: Predicting Response to Cancer Immunotherapy 11MB069
Protein Signature: Method of Diagnosing Chronic Lymphocytic Leukemia 11MB072N
Protein Diagnostic: Mass Spectrometry Diagnostic for BRAF and Heat Shock Proteins 11MB087N
Genetic Signature: Five Gene Signature Predicts Overall and Recurrence-Free Survival in NSCLC 12MB023N
Genetic Signature: TGFß Response Signature in Non-Small Cell Lung Carcinoma 12MA029N
Genetic Signature: O-glycan Pathway Gene Signature to Determine which Ovarian Cancer Patients would have a Survival Benefit from Optimal Surgical Debulking 12MA034
Genetic Signature: Determining Prostate Cancer Recurrence Using Polymorphisms in Angiogenesis Genes 12MA045
Molecular Imaging Probe: Probes for Lung Cancer Intraoperative Guidance 12MA050N
Genetic Signature: E2F/Rb pathway signature for prediction of patient benefit from adjuvant chemotherapy in Non-Small Cell Lung Cancer 12MA069
Molecular Imaging Probe: Novel chemical scaffold for 18F-labeled PET biomarker production 12MB104
Protein Diagnostic: Phosphorylated STAT3 Protein as a Novel Biomarker of Graft Versus Host Disease 13MA002
Multiplex Diagnostic: RNA Sequencing and Mass Spectrometric Method for Detecting Minimal Residual Disease in Multiple Myeloma 13MA009
Genetic Signature: Predicting Recurrence and Benefit From Adjuvant Chemotherapy in Colorectal Cancer 13MA036
Cell Imaging: Apparatus and Method for Selecting Cancer Treatment Regimens for Multiple Myeloma 13MB048N
Molecular Imaging: Texture Feature Analysis of Low-Dose CT Images for Pulmonary Nodule 13MB054
Molecular Imaging: Novel Imaging Software Diagnostic to Determine Survival in Glioblastoma 13MB055
Molecular Imaging: Novel PET Probes of Radiofluorinated Carboximidamides for IDO-Targeted Imaging 13MB056N
Genetic Signature: MicroRNAs that Differentiate High-risk from Low-risk Intraductal Papilary Mucinous Neoplasms of the Pancreas 13MB078
miRNA Diagnostic: Signature to Predict Progression of Barrett’s Esophagus to Esophageal Dysplasia or Adenocarcinoma 13MB080
Genetic Signature: Gene Signature to Predict Distant Metastasis in Stage I Lung Cancer Patients Treated with Surgery 14MA008
Gene signature to predict loco-regional recurrence in stage I-II lung cancer following surgery 14MA014N
Microarray-based gene expression profiling to predict tumor sensitivity to radiotherapy 14MA052N
Antibody Diagnostic: Use of Frabin/FDG4 as a Biomarker to Distinguish Cancer from Normal Prostate Tissue on Biopsy 14MA064
Molecular Imaging: Monoacylated TLR2 Ligand Fluorescent Probe for Detection and Tumor Removal in Pancreatic Cancer Patients 15MA015 
Diagnostic: Intracellular S100A9 Alone or NLRP3 Inflammasome Activation May Be Specific Biomarkers for MDS 15MA021N 
Diagnostic: S100A9 Serum Concentration Levels Predict Lenalidomide Response Duration 15MA031N 
Diagnostic: New Use for 18F-FDG for the MUGA Scan 15MB042N 
Protein Biomarker: Diagnostic for Progression of MDS to AML Using PD-1 or PD-L1 Expression 15MB065
Genetic Signature: Diagnostic to Distinguish Lung Carcinoma from Metastatic Head & Neck Carcinoma 16MB040
Protein Biomarker: Predicting Restoration of Sensitivity to Erythropoietin in MDS Patients treated with Lenalidomide 16MB042
Molecular Imaging Probe: Novel IDO1-Targeting Cancer Diagnostic PET Imaging Agent 16MB044